Butaclamol hydrochloride in newly admitted schizophrenics. 
Butaclamol hydrochloride, a new type of antipsychotic drug, was evaluated by an uncontrolled study of 13 newly admitted schizophrenic patients.  The drug had antipsychotic effects as well as a strong propensity for evoking extrapyramidal side effects.  With the maximal daily doses of 30 mg used in this study, therapeutic results obtained were probably somewhat less than optimal.